FDA Approves Lipfendra: A New Oral Option for Managing High Cholesterol
For decades, individuals with high LDL cholesterol had limited options: statins or injections. Recently, the FDA has prioritized the review of Lipfendra (enlicitide), marking a significant advancement as the first oral medication that inhibits the PCSK9 protein, which is integral to the regulation of bad cholesterol in the body. Previously, treatments targeting PCSK9 were only available through injections, which posed challenges related to cost and accessibility.
PCSK9, produced by the liver, reduces the body's ability to eliminate LDL cholesterol from the bloodstream. By blocking this protein, Lipfendra allows the liver to remove more LDL from circulation, leading to lower blood levels of cholesterol.
Clinical trials involving 3,207 adults with severe high cholesterol, who were already on the maximum tolerated dose of statins, demonstrated the efficacy of Lipfendra. In the first trial, participants with cardiovascular disease or high risk for it started with an average LDL of 96 mg/dL. After 24 weeks, those taking Lipfendra experienced an average LDL reduction of 56% compared to the placebo group. The second trial focused on adults with heterozygous familial hypercholesterolemia (HeFH), an inherited condition leading to high LDL levels. These participants began with an average LDL of 119 mg/dL and saw a 59% reduction after the same duration.
While Lipfendra is not a substitute for statins, it serves as an additional option for adults who still struggle to reach their LDL goals despite adhering to a healthy lifestyle and maximally tolerated statin therapy. It is crucial for individuals considering Lipfendra to be aware of potential side effects. In the HeFH trial, participants reported diarrhea and dizziness more frequently than those on placebo, although no distinct side effects were noted in the cardiovascular disease trial. The dropout rate due to adverse reactions was similar in both trials.
Despite the excitement surrounding new drug developments, the foundation for preventing cardiovascular disease remains a healthy lifestyle. According to the latest ACC/AHA guidelines, a diet rich in vegetables, fruits, whole grains, and lean proteins, combined with at least 150 minutes of moderate-intensity physical activity weekly, is essential. For many, these lifestyle changes can effectively lower LDL levels. When lifestyle modifications and statins are insufficient, Lipfendra provides a promising alternative for those who have exhausted other options in managing their cholesterol.
The approval of Lipfendra as a once-daily pill that can significantly reduce LDL cholesterol represents a major step forward in treatment options for high cholesterol. For individuals managing their cholesterol with lifestyle changes and statins without achieving target levels, discussing this new medication with a healthcare provider may be beneficial.




